VAXX
Vaxxinity Inc - Ordinary Shares - Class A

1,155
Loading...
Loading...
News
all
press releases
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
read more...
Benzinga·1y ago
News Placeholder
More News
News Placeholder
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
Presentation will address the Company's clinical data in Parkinson's diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...
Globe Newswire·1y ago
News Placeholder
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...
Globe Newswire·1y ago
News Placeholder
Vaxxinity (NASDAQ:VAXX) Shares Down 4.5%
Vaxxinity, Inc. (NASDAQ:VAXX Get Free Report) shares dropped 4.5% during trading on Monday . The company traded as low as $0.71 and last traded at $0.72. Approximately 195,541 shares changed...
Zolmax·1y ago
News Placeholder
Vaxxinity announces 'positive' target engagement data from Phase 1 trial
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD 2024
UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patientsLISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc...
Globe Newswire·2y ago
News Placeholder
Private companies in Vaxxinity, Inc. (NASDAQ:VAXX) are its biggest bettors, and their bets paid off as stock gained 22% last week
Key Insights The considerable ownership by private companies in Vaxxinity indicates that they collectively have a...
Simply Wall St·2y ago
News Placeholder
Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of...
Globe Newswire·2y ago
News Placeholder
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...
Globe Newswire·2y ago
News Placeholder
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research...
Globe Newswire·2y ago

Latest VAXX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.